Recently, the authors reported that the ratio of serum IgA to C3 (serum IgA/C3 ratio) is a good marker to distinguish patients with IgA nephropathy from non-IgA nephropathy patients together with serum IgA levels using an international reference preparation (IFCC/CRM470). In this study, the authors investigated whether the serum IgA/C3 ratio might be an indicator of prognostic grading in patients with IgA nephropathy. Two hundred and thirteen patients with IgA nephropathy and 96 other glomerular diseases including diffuse or focal mesangial proliferative glomerulonephritis without mesangial IgA deposition (non-IgA PGN), membranous nephropathy and thin basement membrane syndrome were examined. The levels of serum IgA and C3 in these patients were adjusted by the specified formula to those using international standard serum (IFCC/CRM470) in this study. The results of this study showed the highest levels of IgA/C3 ratio in patients with IgA nephropathy. The serum IgA/C3 ratio appears to gradually increase according to the prognostic grading of this disease. Therefore, measurement of the serum IgA/C3 ratio may be useful for prediction of diagnosis and prognostic grading in patients with IgA nephropathy.

Keywords:
Serum IgA/C3 ratio, Diagnosis, Prognosis, IgA nephropathy
1.
Berger J: IgA glomerular deposits in renal disease. Transplant Proc 1969;1:939–944.
2.
Tomino Y: IgA characteristics; in Berlyne GM, Ronco C (eds): IgA Nephropathy from Molecules to Men. Contrib Nephrol. Basel, Karger, 1999, vol 126, pp 31–32.
3.
Tomino Y, Sakai H, Endoh M, Kaneshige H, Nomoto Y: Detection of immune complexes in polymorphonuclear leukocytes by double immunofluorescence in patients with IgA nephropathy. Clin Immunol Immunopathol 1982;24:63–71.
4.
Whitworth JA, Leibowitz S, Kennedy JS, Cameron JS, Chantler C: IgA and glomerular disease. Clin Nephrol 1976;5:33–36.
5.
Harper SJ, Allen AC, Layward L, Hattersley J, Veitch PS, Feehally J: Increased immunoglobulin A and immunoglobulin A1 cells in bone marrow trephine biopsy specimens in immunoglobulin A nephropathy. Am J Kidney Dis 1994;24:888–892.
6.
Tomino Y, Sakai H, Miura M, Suga T, Endoh M, Nomoto Y, Itoh K, Ikeda N: Discrepancy of serum IgA levels determined by single radial immunodiffusion and laser nephelometry in patients with IgA nephropathy. Am J Med Sci 1985;290:56–60.
7.
Sakai H, Abe K, Kobayashi Y, Koyama A, Shigematsu H, Harada T, Yoshikawa N, Arakawa M, Itoh H, Osawa G, Dohi K, Yamanaka N, Nagasawa T, Kurokawa K: Clinical guidelines of IgA nephropathy. Jpn J Nephrol 1995;37:417–421.
8.
Itoh Y, Ichihara K, Kanno T, Sugawara T, Ohkubo A, Hirabayashi Y, Igarashi S, Kawano K, Iwata S, Saito K, Kawai T: Serum protein standardization project in Japan: Evaluation of an IFCC reference material (RPPHS/CRM470) and establishment of reference intervals. J Clin Lab Anal 1997;11:39–44.
9.
Fink PC, Romer M, Haeckel R, Fateh- Moghadam A, Delanghe J, Gressner AM, Dubs RW: Measurement of proteins with the Behring nephelometer: A multicenter evaluation. J Clin Chem Biochem 1989;27:261–276.
10.
Tomino Y, Suzuki S, Imai H, Saito T, Kawamura T, Yorioka N, Harada T, Yasumoto Y, Kida H, Kobayashi Y, Endoh M, Sato H, Saito K: Measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy. J Clin Lab Anal 2000;14:220–223.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.